@booklet {7043,
	title = {Carfilzomib{\textendash}dexamethasone vs bortezomib{\textendash}dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR},
	journal = {Leukemia},
	year = {2017},
	note = {Export Date: 18 February 2017Article in Press},
	month = {2017},
	abstract = {The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27\%) had high-risk cytogenetics (Kd, n=97 (25\%); Vd, n=113 (28\%)) and 575 (73\%) had standard-risk cytogenetics (Kd, n=284 (75\%); Vd, n=291 (72\%)). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio (HR), 0.65; 95\% confidence interval (CI), 0.45{\textendash}0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95\% CI, 0.33{\textendash}0.58; P<0.0001). Overall response rates were 72.2\% (Kd) vs 58.4\% (Vd) in the high-risk group and 79.2\% (Kd) vs 66.0\% (Vd) in the standard-risk group. In the high-risk group, 15.5\% (Kd) vs 4.4\% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0\% (Kd) vs 7.9\% (Vd) achieved ⩾CR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.Leukemia advance online publication, 3 February 2017; doi:10.1038/leu.2016.390. {\textcopyright} 2017 The Author(s)},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011631341\&doi=10.1038\%2fleu.2016.390\&partnerID=40\&md5=11667e9c85f2255bfce2ff0a1fc1399b},
	author = {Chng, W.-J. and Goldschmidt, H. and Dimopoulos, M.A. and Moreau, P. and Joshua, D. and Palumbo, A. and Facon, T. and Ludwig, H. and Pour, L. and Niesvizky, R. and Oriol, A. and Rosi{\~n}ol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and Goranova-Marinova, V. and Gillenwater, H.H. and Mohamed, N. and Feng, S. and Aggarwal, S. and H{\'a}jek, R.}
}
